Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade
Stéphane Terry, Cécile Dalban, Nathalie Rioux‐Leclercq, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 24, pp. 6749-6760
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

AXL in cancer: a modulator of drug resistance and therapeutic target
Yaoxiang Tang, Hongjing Zang, Qiuyuan Wen, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 47
TAM family kinases as therapeutic targets at the interface of cancer and immunity
Deborah DeRyckere, Justus M. Huelse, H. Shelton Earp, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 755-779
Closed Access | Times Cited: 46
AXL signaling in cancer: from molecular insights to targeted therapies
Monika Yadav, Anuj K. Sharma, Ketki Patne, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
AXL: shapers of tumor progression and immunosuppressive microenvironments
Yihui Liu, Lei Xu, Yuanyao Dou, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
Agnete S.T. Engelsen, Maria L. Lotsberg, Raefa Abou Khouzam, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion
Baiwen Chen, Jiajia Hu, Xianting Hu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 41
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
Giuseppe Procopio, Mélanie Claps, Chiara Pircher, et al.
Tumori Journal (2022) Vol. 109, Iss. 1, pp. 129-137
Open Access | Times Cited: 41
Recent Advances in the Management of Clear Cell Renal Cell Carcinoma: Novel Biomarkers and Targeted Therapies
Valentina Schiavoni, Roberto Campagna, Valentina Pozzi, et al.
Cancers (2023) Vol. 15, Iss. 12, pp. 3207-3207
Open Access | Times Cited: 35
PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives
Zhu Zhao-yang, Yigang Jin, Jing Zhou, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer
Yunong Xie, Haofeng Wu, Yimiao He, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 10
Single-cell transcriptome reveals cellular hierarchies and guides p-EMT-targeted trial in skull base chordoma
Qilin Zhang, Lijiang Fei, Rui Han, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 29
Targeting the epigenome to reinvigorate T cells for cancer immunotherapy
Dian Xiong, Lu Zhang, Zhi‐Jun Sun
Military Medical Research (2023) Vol. 10, Iss. 1
Open Access | Times Cited: 21
Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer
Rui Han, Conghua Lu, Chen Hu, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 6, pp. 1264-1275
Closed Access | Times Cited: 8
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
Dan Yan, H. Shelton Earp, Deborah DeRyckere, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5639-5639
Open Access | Times Cited: 24
Advances in Renal Cell Carcinoma Drug Resistance Models
Yien Xiang, Zheng Ge, Jianfeng Zhong, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 17
Patients with Advanced or Metastasised Non-Small-Cell Lung Cancer with Viscum album L. Therapy in Addition to PD-1/PD-L1 Blockade: A Real-World Data Study
Friedemann Schad, Anja Thronicke, Ralf‐Dieter Hofheinz, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1609-1609
Open Access | Times Cited: 3
Diagnostic, predictive and prognostic molecular biomarkers in clear cell renal cell carcinoma: A retrospective study
Jian Deng, ShengYuan Tu, Lin Li, et al.
Cancer Reports (2024) Vol. 7, Iss. 6
Open Access | Times Cited: 3
The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma
Jiaming Su, Lu Zhou, Zhe Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1–AXL signal relay in liver cancer cells
Toshimitsu Tanaka, Hironori Koga, Hiroyuki Suzuki, et al.
Hepatology International (2023) Vol. 18, Iss. 3, pp. 984-997
Closed Access | Times Cited: 7
Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy
Dian Xiong, Haijun Yu, Zhi‐Jun Sun
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 8, pp. 3416-3431
Open Access | Times Cited: 2
Initial AXL and MCL‐1 inhibition contributes to abolishing lazertinib tolerance in EGFR‐mutant lung cancer cells
Yohei Matsui, Tadaaki Yamada, Yuki Katayama, et al.
Cancer Science (2024) Vol. 115, Iss. 10, pp. 3333-3345
Open Access | Times Cited: 2
Personalized medicine: Clinical oncology on molecular view of treatment
Rafick Costa Dos Santos Da Silva, Nathalia de Andrade Simon, André Alves Dos Santos, et al.
World Journal of Clinical Oncology (2024) Vol. 15, Iss. 8, pp. 992-1001
Open Access | Times Cited: 2
AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy
Austin Rayford, Fabian Gärtner, Maria Ramnefjell, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Two-Front War on Cancer—Targeting TAM Receptors in Solid Tumour Therapy
Agata Mikołajczyk, Filip Mituła, Delfina Popiel, et al.
Cancers (2022) Vol. 14, Iss. 10, pp. 2488-2488
Open Access | Times Cited: 10
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer
Liza C. Villaruz, George R. Blumenschein, Gregory A. Otterson, et al.
Cancer (2023) Vol. 129, Iss. 9, pp. 1319-1350
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top